-
Product Insights
New![]()
Likelihood of Approval Analysis for Mutational Disorders
Overview How likely is it that the drugs in Mutational Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mutational Disorders Overview Mutational disorders, alternatively termed genetic or genomic disorders, stem...
-
Company Profile
![]()
BridgeBio Pharma Inc – Company Profile
BridgeBio Pharma Inc (BridgeBio) is a commercial-stage biopharmaceutical company that develops drugs for genetic diseases and cancer. The company’s pipeline products include precision cardiorenal, mendelian, precision oncology and gene therapy. Its precision cardiorenal and mendelian drugs include acoramidis, encaleret, fosdenopterin, low-dose infigratinib, BBP-418 and BBP-671. BridgeBio’s precision oncology and gene therapy drugs include high-dose infigratinib, BBO-8520, BBP-398, PI3Kα, BBP-954, Pan-KRAS inhibitor, BBP-812, BBP-631 and AAV gene therapy. The company's brands include TRUSELTIQ and NULIBRY. It works in partnership with academic...
Add to Basket
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.